First-in-Human trial tests 'Off-the-Shelf' immune cells to fight aggressive blood cancers
NCT ID NCT04848064
Summary
This early-stage study is testing a new combination treatment for adults with specific types of T-cell lymphoma that have returned or not responded to prior therapy. The treatment involves giving patients immune cells from a healthy donor (called natural killer or NK cells) along with an existing cancer drug called mogamulizumab. The main goal is to find a safe and tolerable dose of this combination and see if it can help control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT PRIMARY CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Ohio State University Comprehensive Cancer Center
RECRUITINGColumbus, Ohio, 43210, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.